- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01456182
Phase 1B- Open Label Dose-Ranging Study of Oral AFX-2 in Adults With Chronic Lymphocytic Leukemia
January 23, 2012 updated by: Afexa Life Sciences Inc
This trial will assess the tolerability and safety of AFX-2 over a range of five dose levels in adults with low-, intermediate- or high-risk Chronic Lymphocytic Leukemia (CLL).
The trial will also determine the impact of dose on quality of life indices and on biological and immune responses, and will assess if there is a maximum tolerated dose and/or dose-limiting toxicity in this study population.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48106
- Saint Jospeh Mercy Health System
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Comprehensive Cancer Center of Wake Forest University
-
-
South Carolina
-
Greenville, South Carolina, United States, 29615
- Cancer Center Of The Carolinas
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adult men and women >18 years of age
- Diagnosis of CLL per NCI Working Group Criteria; with phenotypic evidence (i.e.. flow cytometry or bone marrow biopsy) of chronic lymphocytic leukemia (MEDDRA Code - 10008960; ICD-O3-9823)
- Disease meets criteria for low-risk (Rai Stage 0), intermediate-risk (Rai Stage I- II), or high-risk (Rai Stage III-IV) disease
- Life expectancy of ≥ 3 months at Screening.
- ECOG performance status 0-3
Laboratory parameters (taken < 14 days of Study Day 0):
- Hematologic parameters: Hemoglobin > 9 gm/dL (stable, not dropping); Absolute Granulocyte Count (AGC) > 1.0 x 109/L; Platelets > 50 x 109/L; not requiring immediate transfusion.
- Coagulation: PT/PTT/INR: ± 10% of NL for lab; INR: 1.0-1.43
- BUN < 40; serum Creatinine ≤ 2.0 mg/dL, OR Creatinine Clearance > 90 mL/min/1.73m2 IF serum Creatinine > 2.0 mg/dL
- Liver function tests (AST, ALT, ALP, LDH): < 2.5 x institutional ULN; Total bilirubin: < 2.0 x institutional ULN
- Human Immunodeficiency Virus (HIV) negative
- Pregnancy test: negative urine pregnancy test for females of child-bearing potential,
- Free of disease from prior malignancy/ies for > 2 years, except for basal cell or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast.
- If not surgically sterile, or post-menopausal (> 12 months with no menstrual flow), willing to practice birth control (barrier + contraception) throughout duration of study.
- Able and willing to swallow capsules.
- Willing to limit alcohol intake during the study treatment period.
- Willing to sign the informed consent.
Exclusion Criteria:
- Lymphoproliferative disease other than CLL
- Prior use of the test article (AFX-2), or ginseng-containing products (American, Asian, etc.) ≤ 1 year prior to study entry.
- Known allergy to the test article or ginseng-containing products
- Active infection requiring systemic treatment
Prior or current therapy:
- Splenectomy.
- Currently requiring anticoagulant therapy
- Requiring active treatment for B-CLL or ≤ 28 days post-treatment for B-CLL or other condition requiring: chemotherapy, radiation therapy, monoclonal antibodies, systemic steroids, antihistamines or non-steroidal anti-inflammatory drugs, including ibuprofen, indomethacin, COX-2 inhibitors etc.
- ≤ 10 days: non-steroidal hormonal therapy (other than for contraception or thyroid)
- ≤ 10 days: antibiotic prophylaxis
- History of therapy with immunological reagents, such as allogeneic bone marrow transplant, monoclonal antibody therapy, intravenous immunoglobulin, or hematopoietic stem cell transplantation. (Note: Immunotherapy for allergies is permitted as long as the last treatment was both (a) prior to the CLL diagnosis and (b) > 5 years prior to trial enrollment.)
- < 90 days post treatment with chlorambucil
- < 90 days post general anesthesia
- Uncontrolled intercurrent condition, including, but not limited to, cardiovascular, pulmonary, renal, hepatic, GI, GU, neurologic, metabolic, psychiatric, etc.
- Current or prior investigational product or procedure < 56 days preceding study entry (Baseline -Visit 2; Study Day 0).
- Unwilling to discontinue use of nonprescription (OTC), nutritional or dietary supplements during the study period (as further defined by protocol).
- Pregnant, lactating.
- Any condition, personal or social situation that precludes or limits the ability of the participant to provide informed consent or comply with study requirements.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Dose arm 1
|
Dose level 1
Dose level 2
Dose level 3
Dose level 4
Dose level 5
|
Other: Dose arm 2
|
Dose level 1
Dose level 2
Dose level 3
Dose level 4
Dose level 5
|
Other: Dose arm 3
|
Dose level 1
Dose level 2
Dose level 3
Dose level 4
Dose level 5
|
Other: Dose arm 4
|
Dose level 1
Dose level 2
Dose level 3
Dose level 4
Dose level 5
|
Other: Dose arm 5
|
Dose level 1
Dose level 2
Dose level 3
Dose level 4
Dose level 5
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability will be assessed based on the incidence, duration and intensity of adverse events
Time Frame: 0-8 weeks
|
Adverse events will be graded according to NCI-CTC v4.
|
0-8 weeks
|
Safety and tolerability will also be determined by assessing any changes in study test results from baseline values
Time Frame: 1 week, 4 weeks, 8 weeks
|
Study tests that will determine safety include vital signs, clinical laboratory tests (hematology, serum chemistries, coagulation, urinalysis) and 12-lead EKG
|
1 week, 4 weeks, 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Quality of life indices
Time Frame: 1 week, 4 weeks, 8 weeks
|
1 week, 4 weeks, 8 weeks
|
Maximum tolerated dose and/or dose-limiting toxicity
Time Frame: 1 week, 4 weeks, 8 weeks
|
1 week, 4 weeks, 8 weeks
|
Biological and immune responses
Time Frame: 1 week, 4 weeks, 8 weeks
|
1 week, 4 weeks, 8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Leslie R Ellis, MD, Wake Forest University Health Sciences Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2011
Primary Completion (Anticipated)
March 1, 2013
Study Completion (Anticipated)
May 1, 2013
Study Registration Dates
First Submitted
October 18, 2011
First Submitted That Met QC Criteria
October 19, 2011
First Posted (Estimate)
October 20, 2011
Study Record Updates
Last Update Posted (Estimate)
January 25, 2012
Last Update Submitted That Met QC Criteria
January 23, 2012
Last Verified
January 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AFX-2-2010-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leukemia, Lymphocytic, Chronic, B-Cell
-
National Heart, Lung, and Blood Institute (NHLBI)Active, not recruitingLeukemia, Lymphocytic, Chronic, B-Cell | Chronic Lymphocytic Leukemia | Leukemia, Chronic Lymphatic | B-Cell Chronic Lymphocytic Leukemia | Leukemia, Lymphocytic, Chronic | B-Lymphocytic Leukemia, Chronic | Leukemia, Chronic Lymphocytic, B-Cell | Lymphocytic Leukemia, Chronic, B Cell | Lymphocytic Leukemia...United States
-
National Cancer Institute (NCI)CompletedB-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic LeukemiaUnited States
-
Fred Hutchinson Cancer Research Center/University...WithdrawnB-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia
-
French Innovative Leukemia OrganisationTerminatedB-cell Chronic Lymphocytic Leukemia (B-CLL)France
-
Genzyme, a Sanofi CompanyBayer Healthcare Pharmaceuticals, Inc./Bayer Schering PharmaCompletedB-Cell Chronic Lymphocytic Leukemia (B-CLL)United Kingdom, Belgium, France, United States, Czech Republic, Serbia
-
Shanghai Zhangjiang Biotechnology Limited CompanySuspendedB-cell Chronic Lymphocytic LeukemiaChina
-
Mundipharma Research LimitedTerminatedB-cell Chronic Lymphocytic LeukemiaSpain
-
CelgeneCompletedB-cell Chronic Lymphocytic LeukemiaUnited States, Spain, United Kingdom, Canada, Belgium, Czechia, Hungary, Italy, Poland, Israel, Germany, Ireland, France, New Zealand, Denmark, Australia, Netherlands, Romania, Russian Federation, Sweden, Austria, South Africa, Colo... and more
-
French Innovative Leukemia OrganisationRoche Pharma AGCompletedB-cell Chronic Lymphocytic Leukemia CLLFrance
-
OnxeoCompletedB-cell Chronic Lymphocytic LeukemiaUnited Kingdom
Clinical Trials on AFX-2
-
EndologixActive, not recruitingAbdominal Aortic AneurysmUnited States
-
Affectis Pharmaceuticals AGFGK Clinical Research GmbHCompletedMajor DepressionAustria, Czech Republic, Germany
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI); NRG OncologyCompletedHead and Neck CancerUnited States, Canada
-
Merck Sharp & Dohme LLCActive, not recruitingHead and Neck NeoplasmsUnited States, Australia, Austria, Belgium, Brazil, Canada, Colombia, Czechia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Poland, Spain, Taiwan, Turkey, United Kingdom
-
University College, LondonMoorfields Eye Hospital NHS Foundation Trust; Targeted Genetics CorporationCompletedRetinal DegenerationUnited Kingdom
-
Yuhan CorporationCompletedRheumatic ArthritisKorea, Republic of
-
Medifast, Inc.Completed
-
University of South CarolinaTerminatedSedentary Lifestyle | Knee Osteoarthritis | Knee Injuries | Knee Pain ChronicUnited States
-
University of PennsylvaniaNational Cancer Institute (NCI); PfizerCompleted
-
Metabolic Technologies Inc.National Institute on Aging (NIA); Vanderbilt UniversityCompleted